GSK Says Chronic Hepatitis B Treatment Approved in Japan

MT newswire2026/08/24 08:06

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

04:06 AM EDT, 08/24/2026 (MT Newswires) -- GSK (GSK) announced on Monday that Japan's Ministry of Health, Labor and Welfare has approved the company's drug Hibsago, or bepirovirsen, as a functional cure for chronic hepatitis B virus infection in certain patients. Adult patients who have received at least six months of prior nucleoside/nucleotide analogue therapy and who meet pre-defined viral markers are eligible to receive Hibsago. This is the first global approval for Hibsago, and the first and only functional cure treatment for chronic hepatitis B approved in Japan, reported GSK, in a filing with the London Stock Exchange. Chronic hepatitis B affects nearly one million people in Japan with nationwide efforts underway for screening and treatment, said GSK. GSK said it continues to advance regulatory submissions for Hibsago in multiple nations, with decisions, including the US, expected in the coming months.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Smart ring manufacturer Oura's IPO was oversubscribed by approximately four times, planning to issue 50 million shares at a maximum price of $44 per share, aiming to raise up to $2.2 billions, with a fully diluted valuation of about $15 billions. Against the backdrop of companies like Holtec Nuclear withdrawing their IPO plans due to market conditions, Oura is expected to become the first major IPO in nearly three months to raise over $1 billion, injecting new vitality into the long-dormant U.S. IPO market.

华尔街见闻•2026/09/26 02:06

The Bank of Japan's interest rate hike still fails to impress the market! Hedge funds slash yen long positions by nearly 80%, while dollar long positions increase significantly

After the Bank of Japan failed to deliver a clear enough signal of further interest rate hikes to the market, hedge funds have significantly reduced their bullish bets on the yen.

智通财经•2026/09/26 00:06